The Technical Analyst
Arena Pharmaceuticals Inc [ARNA]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Arena Pharmaceuticals Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $99.99
America/New_York / 31 des 1970 @ 19:00
| RATING 2022-04-15 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/20 | 4/20 | 1/21 | 2/21 | 3/21 | 4/21 | |
| Revenue | n/a | n/a | n/a | n/a | ||
| Gr.Profit | n/a | n/a | n/a | n/a | ||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -9.86 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -1.68x |
| Company: PE -9.86 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 98.85 - 101.13 ( +/- 1.14%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-03-11 | Nova Tina Susan | Sell | 17 776 | Common Stock |
| 2022-03-11 | Nova Tina Susan | Sell | 3 067 | Common Stock |
| 2022-03-11 | Nova Tina Susan | Sell | 4 800 | Stock Option (right to buy) |
| 2022-03-11 | Nova Tina Susan | Sell | 15 000 | Stock Option (right to buy) |
| 2022-03-11 | Nova Tina Susan | Sell | 5 000 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 0.00 |
| Last 100 transactions |
| Buy: 416 073 | Sell: 1 553 839 |
Forecast:
01:40 - $104.05
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $99.99 (0.00% ) |
| Volume | 0 mill |
| Avg. Vol. | 1.473 mill |
| % of Avg. Vol | 0 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ARNA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ARNA
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.
Last 10 Buy Signals
Latest Press Releases
2022-03-11 08:34:00 - Press Release
Pfizer Completes Acquisition Of Arena Pharmaceuticals
New york--(business wire)--pfizer inc. (nyse: pfe) announced today the completion of its acquisition of arena pharmaceuticals, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases. arena pharmaceuticals brings to pfizer a portfolio of diverse and promising development-stage therapeutic candidates in gastroenterology, dermatology, and cardiology, including etrasimod, an oral, selective sphingosine 1-phosphate (s1p) receptor
2021-12-13 17:15:00 - Press Release
Shareholder Alert: Weisslaw Llp Investigates Arena Pharmaceuticals, Inc.
New york, dec. 13, 2021 /prnewswire/ -- weisslaw llp is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of arena pharmaceuticals, inc. ("arena" or the "company") (nasdaq: arna), in connection with the proposed acquisition of the company by pfizer inc. ("pfizer") (nyse: pfe). under the terms of the merger agreement, the company's shareholders will receive $100.00 per share in cash for each share of arena common stock that they hold.
2021-12-13 06:45:00 - Press Release
Pfizer To Acquire Arena Pharmaceuticals
New york & park city, utah--(business wire)--pfizer inc. (nyse: pfe) and arena pharmaceuticals, inc. (nasdaq: arna) today announced that the companies have entered into a definitive agreement under which pfizer will acquire arena, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases. under the terms of the agreement, pfizer will acquire all the outstanding shares of arena for $100 per share in an all-cash transaction for a
2021-10-14 16:05:00 - Press Release
Arena Pharmaceuticals To Release Third Quarter 2021 Financial Results And Provide Corporate Update On November 4
Park city, utah--(business wire)--arena pharmaceuticals, inc. (nasdaq: arna) will release its third quarter 2021 financial results and provide a corporate update on thursday, november 4, 2021, after the close of the u.s. financial markets. the company will host a question and answer session via conference call and live webcast with the investment community the same day at 4:30 pm et. conference call & webcast information when: thursday, november 4, 2021, at 4:30 pm et webcast: conference call will be broadcast live in listen-only mode on the company’s investor relations website at https://invest.arenapharm.com/events-presentations a recording of the conference call will be archived for 30 days after the call...
2021-09-02 08:30:00 - Press Release
Arena Pharmaceuticals To Host Virtual R&d Investor Calls And Participate In Upcoming September Investor Conferences
Park city, utah--(business wire)--arena pharmaceuticals, inc. (nasdaq: arna) today announced they will be hosting two virtual r&d investor calls for analysts and investors focused on the company’s etrasimod programs. the company will also participate in five upcoming investor conferences throughout september. virtual investor call webcast information in addition to presentations by arena’s senior management team, the investor calls will feature presentations by and q&a with renowned key opinion leaders. gastroenterology investor call presenters: robert lisicki, executive vice president and chief commercial officer, arena pharmaceuticals william sandborn, md, distinguished professor of medicine; university of california san diego the video webcast will be broadcast live in listen-only mode from 10:30 a...
Latest News
2022-03-11 11:04:21 - Market Watch
Pfizer closes $6.7 billion acquisition of Arena Pharmaceuticals
Shares of Pfizer Inc. PFE, +2.32% were up 2.0% in trading on Friday after the company said it closed its $6.7 billion acquisition of Arena Pharmaceuticals Inc. Arena is developing treatments for immuno-inflammatory diseases like ulcerative colitis and atopic dermatitis. It has said it expects to share data from a Phase 3 clinical trial testing one of those experimental therapies, etrasimod, in ulcerative colitis patients during the first quarter of his year.
2022-03-09 06:24:06 - InvestorPlace
7 Biotech Stocks With Key Catalysts in March
These seven stocks have some key catalysts lined up for March with the potential to move their price actions in big ways. The post 7 Biotech Stocks With Key Catalysts in March appeared first on InvestorPlace.
2022-02-28 15:05:13 - Schaeffers Research
11 Marijuana Stocks on Fire to Close February
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update , where we recap what happened in the world of marijuana stocks, and look at how the cannabis industry is evolving as we make our way through 2022.
2022-02-24 19:15:57 - Zacks Investment Research
Arena (ARNA) Q4 Loss Wider Than Expected, Etrasimod in Focus
Arena Pharmaceuticals (ARNA) misses on Q4 bottom line. Top-line data from several phase III studies on etrasimod are slated for release in 2022.
2022-02-17 19:30:00 - Invezz
Top 3 weed stocks to put on your watch list this year
2022-01-18 16:33:53 - GuruFocus
Pharma Giants Go After $10 Billion Market With RSV Drugs
GlaxoSmithKline PLC ( GSK , Financial), Pfizer Inc. ( PFE , Financial) and Johnson & Johnson ( JNJ , Financial) should all know about mid-year if the shots they're developing for a common and potentially fatal virus is effective. No, the it isn't for Covid-19, but for respiratory syncytial virus, which causes an estimated 177,000 hospitalizations among older adults each year and 58,000 in children under five.
2021-12-23 12:01:00 - Market Watch
Cannabis Watch: Pfizer's Arena Pharma deal may lead drug company to a cannabis-based treatment
Pfizer Inc.'s presentation of its pending $6.7 billion acquisition of clinical-stage drug company Arena Pharmaceuticals Inc. contained no mention of cannabis.
2021-12-22 11:28:14 - Zacks Investment Research
Should You Buy Arena Pharmaceuticals, Inc. (ARNA) After Golden Cross?
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
2021-12-15 22:13:38 - Seeking Alpha
Abivax: Potentially The Next Arena Pharmaceuticals, Most Ideal Big Pharma M&A Target In 2022
Arena Pharmaceuticals got acquired by Pfizer for US$ 6.7 Bn (~100% valuation) on December 12th. As a result, the market for late-stage oral IBD candidates that big pharma can acquire is thinning.
2021-12-14 10:44:30 - Zacks Investment Research
Pfizer (PFE) to Buy Arena, Boost Immuno-Inflammatory Pipeline
Pfizer (PFE) signs an agreement to acquire Arena Pharmaceuticals for $6.7 billion in cash. Stock rises.